EQT agrees to buy Corza Medical’s TachoSil biosurgery business

  • EQT agreed to buy Corza Biosurgery from Corza Medical, acquiring the TachoSil surgical hemostat and sealant patch business.
  • Transaction expected to close in Q4 2026, subject to customary conditions and approvals.
  • TachoSil is used in more than 50 countries; the business has a manufacturing site in Linz, Austria, with about 400 employees.
  • Sheri McCoy will become board chair of the standalone company on closing.
  • EQT plans to back growth via U.S. expansion, broader indications, geographic rollout, innovation, and add-on acquisitions in biosurgery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQT AB published the original content used to generate this news brief via PR Newswire (Ref. ID: EN99235) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.